In a mouse model of paediatric pneumonia, supplementation with Uro A resulted in a decrease in lung inflammation and damage (Reference Cao, Wan and Wan69)
Body weight of the test subjects was measured when the patients were screened, when they were randomly assigned to treatment groups, and at weeks 2, 4, 6, 8, 10, 14, 18, 22, 26, and 32 [1]
While typically requiring ongoing treatment, this represents meaningful disease modification
That answer requires knowing where you stand, and knowing where you stand requires a benchmark built from employers who actually look like you, not a national average that flattens the variation that matters
K.ViswanathanM.KentR